NCT02008721 - Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

December 31, 2016

Conditions

Multiple System Atrophy

Interventions

DRUG

EGCG as putative neuroprotective agent

Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent

DRUG

Placebo

Trial Locations (12)

13353

Charité - Universitätsmedizin Berlin, Berlin

14547

Kliniken Beelitz GmbH, Neurologisches Fachkrankenhaus für Bewegungsstörungen, Beelitz-Heilstätten

23562

Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck

34128

Paracelsus-Elena-Klinik Kassel, Kassel

35043

Philipps Universität Marburg, Marburg

40225

Heinrich-Heine-Universität, Neurologische Klinik, Düsseldorf

72076

Eberhard Karls Universität Tübingen, Tübingen

81377

Neurology Department, Ludwig-Maximilians University, München

81675

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, München

89081

Universitätsklinikum Ulm, Ulm

01062

Technische Universität Dresden, Dresden

04103

Universität Leipzig, Leipzig

All Listed Sponsors

collaborator

German Center for Neurodegenerative Diseases (DZNE)

OTHER

collaborator

Deutsche Parkinson Vereinigung

OTHER

collaborator

German Foundation for Neurology

OTHER

collaborator

ParkinsonFonds Deutschland gGmbH

OTHER

lead

Dr. Johannes Levin

OTHER